The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Emapalumab for Hemophagocytic Lymphohistiocytosis: Adult Considerations

Anti-interferon-gamma antibody for primary and secondary HLH

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Emapalumab for Hemophagocytic Lymphohistiocytosis: Adult Considerations?

Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with uncontrolled immune activation and cytokine storm.

Primary (familial) HLH is genetic; secondary HLH is triggered by infection, malignancy, autoimmunity, or drugs.

Interferon-gamma is a central cytokine driving macrophage activation and tissue damage in HLH.

Emapalumab binds and neutralizes interferon-gamma, dampening the inflammatory cascade.

Approved as second-line therapy after etoposide-based protocols (HLH-94/2004) in primary HLH; adult use guided by similar principles.

Symptoms

Persistent unexplained fever (often greater than 38.5 degrees Celsius).
Cytopenias affecting two or more cell lines: anemia, thrombocytopenia, neutropenia.
Splenomegaly, sometimes massive.
Hypertriglyceridemia and/or hypofibrinogenemia.
Markedly elevated ferritin (often greater than 10000 ng/mL), elevated soluble CD25.

Risk Factors

Underlying malignancy, especially lymphomas (T-cell, NK-cell).
Active viral infection: EBV, CMV, HIV, hepatitis viruses.
Autoimmune disease (systemic lupus, Still disease, juvenile idiopathic arthritis).
Genetic predisposition: PRF1, UNC13D, STX11, STXBP2 mutations.
Recent immunosuppression or stem cell transplantation.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent fever with cytopenias and unexplained organ dysfunction.
  • Rapidly worsening clinical status with multi-organ failure features.
  • Marked hyperferritinemia (greater than 10000 ng/mL) suggesting HLH.
  • New neurological symptoms during HLH treatment.
  • Bleeding or coagulopathy in setting of suspected HLH.

Treatment Methods

01
Emapalumab intravenous starting dose 1 mg/kg every 3 days, titrated based on response and ferritin trends.
02
Concurrent dexamethasone for additional immunosuppression.
03
Treatment of underlying trigger essential: chemotherapy for malignancy, antimicrobials for infection.
04
Allogeneic hematopoietic stem cell transplantation curative for primary HLH after disease control.
05
Monitor for opportunistic infections, especially mycobacterial, due to interferon-gamma blockade.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.